These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2465966)

  • 1. Preparation and heat-treatment of factor-IX-concentrates.
    Stampe D; Wieland B; Köhle A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):523-7. PubMed ID: 2465966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
    Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
    Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Improvement in anti-hemophilic preparations and its problems. 2. Inadequacy of the heat treatment of factor concentrates on the inactivation of non-A, non-B hepatitis virus].
    Inagaki M; Osano M
    Rinsho Ketsueki; 1988 May; 29(5):635-9. PubMed ID: 3145994
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
    McLaughlin LF; Drummond O; MacGregor IR
    Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
    Benny AG; Ockelford PA; Johns AS; Woodfield DG; Berry EW
    N Z Med J; 1986 Jun; 99(803):408-9. PubMed ID: 3461352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and properties of human factor IXa.
    Váradi K; Elödi S
    Thromb Haemost; 1976 Jun; 35(3):576-85. PubMed ID: 10636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No detectable alterations in immunogenicity following terminal severe dry-heat treatment of high-purity factor VIII (Liberate) and factor IX (HP9) concentrates.
    MacGregor IR; McLaughlin LF; MacGregor MC; Prowse CV; Pepper DS
    Vox Sang; 1995; 69(4):319-27. PubMed ID: 8751301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor IX concentrates .
    Ménaché D
    Thromb Diath Haemorrh; 1975 Jun; 33(3):600-5. PubMed ID: 1154314
    [No Abstract]   [Full Text] [Related]  

  • 14. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 15. [Technology optimization and properties study of factor IV complex concentrates].
    Zeng R; Yu R; Li X; Wu Y; Qi H
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):142-4. PubMed ID: 15600207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The isolation of prothrombin, Factor IX and Factor X from human Factor IX concentrates.
    Modi GJ; Blajchman MA; Ofosu FA
    Thromb Res; 1984 Dec; 36(6):537-47. PubMed ID: 6084874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs.
    Littlewood JD; Dawes J; Smith JK; Feldman PA; Haddon ME; McQuillan TA; Foster PR; Ferguson J; Prowse CV
    Br J Haematol; 1987 Apr; 65(4):463-8. PubMed ID: 3580303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preparation of factor IX concentrate with the use of DEAE-cellulose and its therapeutic results].
    Uszyński L; Poszwiński P
    Acta Haematol Pol; 1971; 2(2):109-14. PubMed ID: 5170671
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
    Limentani SA; Gowell KP; Deitcher SR
    Thromb Haemost; 1995 Apr; 73(4):584-91. PubMed ID: 7495063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers.
    Bakaltcheva I; O'Sullivan AM; Hmel P; Ogbu H
    Thromb Res; 2007; 120(1):105-16. PubMed ID: 16962645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.